Swedish Orphan Biovitrum AB (publ) provided revenue guidance for the year 2024. For the period, the company anticipated revenue to grow by a high single-digit percentage at CER.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
275.8 SEK | -0.14% | -1.78% | +3.30% |
May. 24 | Sobi North America Gets FDA Fast Track Designation for Rheumatic Disease Complication Treatment | DJ |
May. 14 | Swedish Orphan Biovitrum AB Elects Zlatko Rihter as New Board Member | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.30% | 8.85B | |
-1.64% | 90.28B | |
-1.97% | 39.5B | |
-15.47% | 31.71B | |
+61.28% | 26.41B | |
-22.81% | 14.34B | |
-8.82% | 12.89B | |
-11.77% | 11.8B | |
-45.97% | 10.95B | |
-13.92% | 7.53B |
- Stock Market
- Equities
- SOBI Stock
- News Swedish Orphan Biovitrum AB
- Swedish Orphan Biovitrum AB Provides Revenue Guidance for the Year 2024